LABA/LAMA vs placebo
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes onlyOR 1.06 [0.88, 1.28]22 studies · 10536 participantsHigh